Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. today announces the successful results of the Phase 2b PROMISE trial which were presented by Dr. A. Osama Gaber, an investigator for the PROMISE trial, at the 2008 American Transplant Congress in Toronto, Canada. The presentation detailed the final data ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. will hold a conference call to discuss final Phase 2b PROMISE kidney transplant data for the Company's lead immunosuppressive drug, voclosporin, on Wednesday, June 4th at 9:00 a.m. ET/7:00 a.m. MT. As previously announced, the final Phase 2b kidney transplant trial (PROMISE) results will be presented during an ...
HarbourVest Global Private Equity Limited
St Peter Port, Guernsey (ots/PRNewswire) - HarbourVest Global Private Equity Limited ("HVPE") has been advised of the proposed sale of ersol Solar Energy AG, one of HVPE's 25 largest underlying company investments, by Ventizz Capital Fund II, LP ("Ventizz"). At the announced price, the sale of ersol to Robert Bosch GmbH would result in a gain in NAV for HVPE of ...
Amsterdam, The Netherlands (ots/PRNewswire) - - Impact Spreading Outside of Financial Services Sector Globally Credit crisis related factors such as tight credit and increased payment defaults are expected to result in slower growth and growing business defaults over the remainder of 2008 and into 2009. A 14 country survey, covering businesses in North America, Europe and Australia, sponsored by Atradius found ...
Johannesburg, South Africa (ots/PRNewswire) - - More than 5 Million South Africans Living with HIV Gain Access to First and Only Co-formulated, Non-refrigerated Protease Inhibitor Abbott (NYSE: ABT) today announced that the new tablet formulation of its protease inhibitor Aluvia(R) (lopinavir/ritonavir), for the treatment of HIV-1, is now available to ...
Halifax, Nova Scotia (ots/PRNewswire) - - First Results to be Announced Marine scientists from around the world will be homing in on Halifax next week when they converge on Dalhousie University for the First Annual Ocean Tracking Network Conference June 4 to June 6. The conference is the official launch of the Ocean Tracking Network and appropriately ...
San Jose, California (ots/PRNewswire) - Atmel(R) Corporation (Nasdaq: ATML), an inventor and leading provider of swipe sensor technology and solutions, announced today that its FingerChip(R) fingerprint sensor solution has been selected by Rise Computer, Inc. for its RX5622 LCD PC. Rise will showcase this biometrics-capable LCD PC during 2008 Computex in Taipei, ...
London (ots/PRNewswire) - MrTed Ltd., leading solution provider of talent acquisition solutions, announced today the appointment of Nicholas Adams, as the new country manager for UK/Ireland. Adams succeeds Jamie Davies, who will be responsible for the international sales activities of MrTed. "Nicholas is a talented manager, motivator, and he's deeply committed to the success of MrTed in the UK and Irish markets," ...
New York (ots/PRNewswire) - A joint venture led by Hilco Consumer Capital, L.P. ("HCC"), Gordon Brothers Brands, LLC ("GBB"), and Bluestar Alliance ("Bluestar"), in partnership with Windsong Brands, LLC and Crystal Capital, announced on May 29, 2008 court approval to purchase The Sharper Image brand and other ...
Instituto Gallego de Oftalmologia
Berlin, Germany (ots/PRNewswire) - - First Crossover Study to Compare Fixed Combination Therapies Presented at EGS Greater intra-ocular pressure (IOP) lowering benefit can be achieved for glaucoma patients treated with a fixed combination of bimatoprost and timolol (Ganfort(R), Allergan), new data ...
We are advised by Merck Serono that journalists and other readers should disregard the news release "Erbitux Significantly Prolongs Survival in 1st-Line Treatment of Non-Small Cell Lung Cancer" NYSE:SRA, issued today due to premature release. This release will be reissued at a later date. ots Originaltext: Merck Serono Im Internet recherchierbar: http://www.presseportal.ch Contact: Contact: Dr. Raphaela ...
Chicago and Darmstadt, Germany (ots/PRNewswire) - - New Data Provides the Basis for the Future Role of Erbitux (cetuximab) as a Standard in Combination With Platinum-Based Chemotherapy in the 1st-Line Treatment of Patients With Non-Small Cell Lung Cancer (NSCLC) - Location: Annual Meeting of the American Society of Clinical Oncology (ASCO) 2008, Chicago, ...
Basel, Switzerland (ots/PRNewswire) - - Data From Pivotal Phase III AVADO Study Presented at ASCO for the First Time Avastin (bevacizumab), significantly improves the time patients with metastatic breast cancer live without their disease getting worse ("progression-free survival") when combined with a ...
Basel, Switzerland (ots/PRNewswire) - - Results Confirm Previously Demonstrated Survival Advantages of Tarceva in This Difficult-to-Treat Disease - ABSTRACT No: 4507 Adding Avastin (bevacizumab) to a combination of Tarceva (erlotinib) and chemotherapy significantly improves the time patients with metastatic pancreatic cancer live without their disease ...
Basel, Switzerland (ots/PRNewswire) - - Thousands Of Patients Benefit Provided From Avastin-Based Therapy A wealth of new Avastin (bevacizumab) data will be presented at the 44th annual meeting of the American Society of Clinical Oncology (ASCO) in Chicago confirming that Avastin-based therapy is essential for patients with metastatic colorectal cancer ...
Stockholm (ots/PRNewswire) - - Report Benchmarks the Current State of Lung Cancer Care Across Europe The fragmented organization and management of lung cancer diagnosis and care in many European countries are exacerbating already poor survival rates amongst patients with the disease. That is the conclusion of a new report from a group of leading ...
Chicago, Illinois (ots/PRNewswire) - - Tarceva Extends Length and Quality of Life in Largest Non-Small Cell Lung Cancer (NSCLC) Phase IV Study Ever Conducted - For non-US and non-UK Media Only New data presented at ASCO 2008 from TRUST(1), the largest non-small cell lung cancer (NSCLC) Phase IV trial ever conducted, show that a broad range of NSCLC ...
Basel, Switzerland (ots/PRNewswire) - - Tolerability is an Increasingly Important Factor When Selecting Treatment Options for Patients - ABSTRACT No: 5110 (Poster 6H) Data presented at the largest oncology meeting in the world, the American Society of Clinical Oncology (ASCO), shows that the costs ...
HarbourVest Global Private Equity Limited
St Peter Port, Guernsey (ots/PRNewswire) - HarbourVest Global Private Equity Limited ("HVPE"), a closed-end Investment company listed on Euronext Amsterdam by NYSE Euronext, today announces its audited results for the period from inception to 31 January 2008 and the publication of its first Annual Report. As ...
Basel, Switzerland (ots/PRNewswire) - New data from a Phase II trial presented at the American Society of Clinical Oncology (ASCO) 2008 meeting showed that half of the patients with advanced, HER2-positive metastatic breast cancer whose disease had progressed during a Herceptin-containing regimen benefited from a ...
Vancouver, Canada (ots/PRNewswire) - Oremex Resources Inc. (TSX-V: ORM) (the Company) today provided an update on the status of surface access at their Tejamen Silver Property (Tejamen), State of Durango, Mexico. Based on a firm decision by the Governor of the State of Durango to assist the parties involved, and to achieve social and economic benefits for the region, discussions with the Ejido of Tejamen are being ...
Turnhout, Belgium (ots/PRNewswire) - - New Generation Compound Provides Significant Benefit in Patients who do not Adequately Respond to Laxatives New phase III data for RESOLOR(R) (prucalopride) published today in The New England Journal of Medicine (NEJM) shows statistically and clinically significant improvement of bowel function and reduced severity of ...
Turnhout, Belgium (ots/PRNewswire) - Movetis today announced that the European Medicines Agency (EMeA) has accepted the Marketing Authorization Application (MAA) submission for RESOLOR(R) (prucalopride) as a treatment for chronic constipation in adults in whom laxatives fail to provide adequate relief. RESOLOR is a new selective, high affinity 5-HT4 receptor ...
Collegeville, Pennsylvania (ots/PRNewswire) - Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the Company's investigational 13-valent pneumococcal conjugate vaccine for infants and toddlers. Wyeth is ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. announced today that voclosporin is positioned to enter a Phase 1 clinical trial as the drug utilized in the CINATRA(TM) Drug Coated Coronary Stent system developed by the Company's partner, Atrium Medical Corporation. Atrium has received approval from the ...
London (ots/PRNewswire) - - Year-Long Campaign Titled 'Optimum Health and Nutrition' to Focus on the Link Between Nutrition and Digestive Health - Poor Digestive Health Affects Millions Worldwide and Seriously Impacts Quality of Life, yet few Seek Medical Advice - WGO and Danone Committed to Working ...
Edmonton, Canada (ots/PRNewswire) - Isotechnika Inc. (TSX:ISA) today announced positive results from the Phase 2b PROMISE trial which evaluated the Company's lead drug, voclosporin , in de novo kidney transplant patients. This trial was designed to determine the most appropriate dosing strategy for the Phase 3 program in kidney transplantation. "PROMISE has shown that the efficacy of voclosporin is statistically ...
Vancouver, British Columbia (ots/PRNewswire) - Mawson Resources Limited ("Mawson") TSX - MAW; Frankfurt - MRY. Michael Hudson, President & CEO, announces the first results from the Company's 40 hole, 1,724 metre winter diamond drill program at the Tasjo uranium - rare earth element (REE) - phosphate project in Sweden. Results are available for the first 8 holes (BODDD08001 to BODDD08004, BODDD08007, BODDD08013 and ...
Abbotsford, British Columbia (ots/PRNewswire) - ICS Copper Systems Ltd. (ICX:TSX.V) reports that it has arranged a private placement of 2,750,000 units at a price of CAD$0.40 per Unit for gross proceeds of CAD$1,100,000. Each Unit will consist of one common share and one full warrant entitling the holder to purchase a common share at a price of CAD$0.50 for a period of 24 months after closing. Completion of the ...
Amsterdam Molecular Therapeutics B.V
Amsterdam, The Netherlands (ots/PRNewswire) - - Production Increase Brings Large Disease Areas Within Reach Amsterdam Molecular Therapeutics (Euronext: AMT), a leader in the field of human gene therapy, today announced that it obtained a Cooperative Research and Development Agreement from the National Heart, Lung, and Blood Institute (NHLBI) of the National ...